First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
暂无分享,去创建一个
K. Asano | T. Akizawa | M. Fukagawa | J. Kazama | Daisuke Honda | K. Yokoyama | F. Koiwa | D. Honda
[1] F. Locatelli,et al. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology , 2019, Journal of Nephrology.
[2] T. Akizawa,et al. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[3] Jena Patel,et al. Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis. , 2018, P & T : a peer-reviewed journal for formulary management.
[4] T. Sakairi,et al. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. , 2018, Bioorganic & medicinal chemistry letters.
[5] T. Akizawa,et al. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro , 2018, PloS one.
[6] T. Nickolas,et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] K. Reinier,et al. Serum Calcium and Risk of Sudden Cardiac Arrest in the General Population , 2017, Mayo Clinic proceedings.
[8] D. Wheeler,et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) , 2017, Kidney international supplements.
[9] G. Chertow,et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial , 2017, JAMA.
[10] Benjamin Wu,et al. Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing , 2016, Kidney international reports.
[11] J. P. Perez Ruixo,et al. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium‐sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis , 2015, Journal of clinical pharmacology.
[12] Zhen Wang,et al. Reversible cardiac dysfunction associated with hypocalcemia: a systematic review and meta-analysis of individual patient data , 2014, Heart Failure Reviews.
[13] S. Fukuhara,et al. Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan , 2013, Kidney international supplements.
[14] K. Iseki,et al. Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[15] John Cunningham,et al. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[16] D. Coyne,et al. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients , 2010, Hemodialysis international. International Symposium on Home Hemodialysis.
[17] Eiji Uchida,et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] B. Culleton,et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.
[19] F. Locatelli,et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.
[20] S. Rosansky,et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.
[21] W. Goodman,et al. Recent developments in the management of secondary hyperparathyroidism. , 2001, Kidney international.
[22] F. M. van der Sande,et al. Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] P. Squires,et al. Expression of the calcium-sensing receptor on human antral gastrin cells in culture. , 1997, The Journal of clinical investigation.
[24] M. Kleerekoper,et al. Blood pressure response to changes in serum ionized calcium during hemodialysis. , 1986, Annals of internal medicine.